{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-074293","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.933044+00:00","generated_at":"2026-05-17T15:19:20.967605+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Raphael Pharma board member resigns; Zvi Laufer Laor appointed as director","bullets":["Dr. Igal Louria Hayon resigned from Board effective Aug 1, 2025; no disagreement; remains CTO.","On Aug 7, 2025, Board appointed Zvi Laufer Laor (age 73, lawyer) to fill vacancy.","Board determined Mr. Laufer qualified and independent under relevant securities laws."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-074293","json":"https://secwatch.observer/filing/0001213900-25-074293.json","markdown":"https://secwatch.observer/filing/0001213900-25-074293.md","text":"https://secwatch.observer/filing/0001213900-25-074293.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390025074293/0001213900-25-074293-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390025074293/ea0252565-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:19:20.967605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}